PER

Advancing #healthcare through continuing medical education live and online experiences in #oncology, #psychiatry, #cardiology, and so much more.

[PER @gotoPER]

📽️ 1, 2, 3... Action! 📽️This is PER — as told by the people who lived it. Hear from some of our attendees on what the PER experience truly means to them. Learn more about what PER has to offer by visiting https://t.co/5xyYscoTbs #gotoPER #testimonialtuesday

[PER @gotoPER]

Tumor Board: Enhancing Pathologic Identification and Diagnostic Precision in Low-Grade Serous Ovarian Cancer https://t.co/qwsPn9sMvT

[PER @gotoPER]

🎥 A message from our Co-Chair, Edgardo Santos, MD
Join Dr. Santos and leading experts from across the field for the 24th Annual Miami Lung Cancer Conference®, January 29–31, 2027, in Miami, FL.
📅 January 29–31, 2027
📍 Miami, FL
#MiamiLung #LungCancer #GoToPER

[PER @gotoPER]

Redefining Extensive-Stage SCLC https://t.co/FYnDS3qWlR

[PER @gotoPER]

https://t.co/FYnDS3qowj

[PER @gotoPER]

Cases and Conversations: Redefining EPNEC Diagnosis and Management—Integrating DLL3 Into Pathology Practice https://t.co/SFGx37uK3u

[PER @gotoPER]

ISGIO Spotlight CE: RAS Precision Pathways in RAS-Mutant GI Malignancies https://t.co/qpwIHr0XT5

[PER @gotoPER]

Session on Presbyopia Management https://t.co/oyk5JEaGOa

[PER @gotoPER]

Improving Identification and Management of Patients w/ Tardive Dyskinesia https://t.co/gMkUyMrFVk

[PER @gotoPER]

Advancing Precision Care in HER2-Positive Gastroesophageal Adenocarcinomas https://t.co/Sn1f1rlh1u

[PER @gotoPER]

Long-Acting Injectable Agents in Patients w/ Schizophrenia https://t.co/Y8Z76JRvOj

[PER @gotoPER]

Integrating Glutamatergic Agents to Advance Care for Patients w/ MDD https://t.co/EB7xytfqvd

[PER @gotoPER]

How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2- Breast Cancer https://t.co/D2R6KsYBXD

[PER @gotoPER]

Advancing Precision Care in HER2-Positive Gastroesophageal Adenocarcinomas https://t.co/QuLhk2ns9T

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Maximizing Outcomes with SERDs in HR+/HER2- MBC – What Should We Do After CDK4/6 Inhibition?
Date: Monday, December 7th, 2026
Scientific Session: 7:00 PM – 8:30 PM CST
Location: Henry B. Gonzalez Convention Center | San Antonio, TX & Virtual
Registration: https://t.co/dBpVfUX7Sp

[PER @gotoPER]

Session on Ocular Toxicities https://t.co/KzyxBnDgUl

[PER @gotoPER]

Advancing Precision Care in HER2-Positive Gastroesophageal Adenocarcinomas https://t.co/FL7NpwUFKz

[PER @gotoPER]

Cases and Conversations: HER2-Positive Breast Cancer https://t.co/g05nt6hs4n

[PER @gotoPER]

@RKSayyid Featuring @zklaassen_md, @KSMurrayUro, and @RKSayyid

[PER @gotoPER]

Join us for an interactive, case-based discussions on personalizing ARPI therapy, treatment intensification, sequencing, and managing treatment-related adverse events.

📍 Hilton San Diego Bayfront and Virtual
🗓️ December 1, 2026
🔗 Register: https://t.co/MgoCeMFPLQ
@RKSayyid

[PER @gotoPER]

Community Oncology Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease https://t.co/EzYOhABfT0